Page 5,366«..1020..5,3655,3665,3675,368..5,3805,390..»

Stem Cell Transplant Hangout – Video

Posted: Published on May 3rd, 2013

Stem Cell Transplant Hangout Lymphoma survivor, Greg Dafoe speaks about his experience receiving a Stem Cell Transplant. Dr. Pike speaking to the research behind Stem Cell Transplants an... By: LymphomaTV … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Stem Cell Transplant Hangout – Video

Stem Cell Treatments for Spinal Cord Injury: Theo K. – Stem Cell Institute Panama – Video

Posted: Published on May 3rd, 2013

Stem Cell Treatments for Spinal Cord Injury: Theo K. - Stem Cell Institute Panama Theo Kostoulas is a T-6 complete spinal cord injury patient. He received a course of 16 stem cell therapy injections using umbilical cord-derived stem cells ... By: cellmedicine … Continue reading →

Posted in Stem Cell Treatments | Comments Off on Stem Cell Treatments for Spinal Cord Injury: Theo K. – Stem Cell Institute Panama – Video

Cell Therapeutics Reports First Quarter 2013 Financial Results

Posted: Published on May 3rd, 2013

SEATTLE, May 2, 2013 /PRNewswire/ -- Cell Therapeutics, Inc.(CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we generated initial commercial sales of PIXUVRI in countries in the European Union where there is market access pending the completion of the reimbursement process," said James Bianco, M.D., President and CEO of CTI. "Although it is early in the launch, we are pleased with the interest and receptivity of PIXUVRI by key lymphoma opinion leaders who treat patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) and who recognize the significant unmet need that exists for these patients. In addition, our Phase 3 PERSIST-1 clinical trial of pacritinib, an oral, once-daily JAK2/FLT3 inhibitor, in myelofibrosis continues to progress with the opening of additional sites and growing enrollment." First Quarter and Recent Highlights European Union (E.U.) Commercial Research and Development Corporate First Quarter 2013 Financial Results Total revenues for the first quarter of 2013 were $1.1 million. The revenues were solely attributable to net product sales of PIXUVRI. CTI sells PIXUVRI directly to health care providers and through a limited number of wholesale distributors in the E.U.CTI records product … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Cell Therapeutics Reports First Quarter 2013 Financial Results

Robert Sullivan, PhD, Dean of Rady School Of Management, to Join Stemedica Board of Business Advisors

Posted: Published on May 3rd, 2013

San Diego, CA (PRWEB) May 02, 2013 Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert Sullivan, PhD, dean of the Rady School of Management at the University of California, San Diego (UC San Diego) has agreed to join the Companys Business Advisory Board. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management. As an Advisor, Dean Sullivans specific focus will be Stemedicas newly formed Cardiology Division which aims to advance Stemedicas national and international clinical trials in chronic heart failure, acute myocardial infarct and other cardiac conditions. Within this Division, Dr. Sullivan will assist the Company as a liaison between not only the San Diego biotech and business communities, but with organizations worldwide. As the founding dean of the Rady School of Management, Dr. Sullivan has increased the schools brand in San Diego and throughout the world. He has successfully recruited top-tier faculty from universities such as the University of Chicago, Massachusetts Institute of Technology (MIT), New York University, Northwestern, Princeton, Stanford, the Wharton School and Yale. In 2011, Dr. Sullivan was elected vice chair-chair elect of the Association to Advance Collegiate Schools of Business (AACSB … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Robert Sullivan, PhD, Dean of Rady School Of Management, to Join Stemedica Board of Business Advisors

Cytomedix AutoloGel(TM) Registry to Be Featured at the Symposium on Advanced Wound Care (SAWC-SPRING) on May 5, 2013

Posted: Published on May 3rd, 2013

GAITHERSBURG, MD--(Marketwired - May 2, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that AutoloGel will be featured in oral and poster presentations at the Symposium on Advanced Wound Care (SAWC), that is being held in Denver, Colorado on May 1- 5, 2013. Dr. Caroline Fife, Chief Medical Officer of Intellicure and Medical Director at the St. Luke's Episcopal Hospital The Woodlands Center for Wound Healing, will deliver the oral presentation. Presentation Details Time: Saturday, May 5, 2013 from 4:30pm-5:30pm Abstract #: Oral - 40.4 Poster - CR-23 Title: Harnessing Electronic Medical Record Capabilities for Prospective Clinical Research: The Platelet Rich Plasma (PRP) Registry for Coverage with Evidence Development (CED) Location: Colorado Convention Center, Denver, Colorado Dr. Fife's oral presentation will outline the benefits of the EHR (electronic health record) system that is being used in the CED (Coverage with Evidence Development) program for AutoloGel.An EHR system with structured language has been customized to automatically perform the acquisition of data and verification of source in both the randomized trial and non-randomized cohort trials that make up the AutoloGel CED program. Only wound centers utilizing this EHR … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Cytomedix AutoloGel(TM) Registry to Be Featured at the Symposium on Advanced Wound Care (SAWC-SPRING) on May 5, 2013

Rheumatoid polyarthritis stem cell treatment – Rejuvaa – Video

Posted: Published on May 3rd, 2013

Rheumatoid polyarthritis stem cell treatment - Rejuvaa An elderly patient, Gurbaksh Kaur who was suffering from Rheumatoid Polyarthritis for last 20 years is sharing her stem cell treatment experience in the vide... By: Rejuvaa … Continue reading →

Comments Off on Rheumatoid polyarthritis stem cell treatment – Rejuvaa – Video

International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting

Posted: Published on May 2nd, 2013

CARLSBAD, CA--(Marketwired - May 1, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced that Dr. Ruslan Semechkin, VP of Research and Development, will present additional data from the primate study of the use of neuronal cells for the treatment of Parkinson's disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013 at the Salt Palace Convention Center in Salt Lake City, UT. The results, including more detailed analysis of the safety and functional activity of the cells, will be presented orally at the following session: Session: Stem Cell Engineering and Therapy Date: Thursday, May 16, 2013 Time: 2:00 PM Room: Ballroom D Title: Cell Replacement Therapy for Parkinson's Disease with Neuronal Cells Derived from Human Parthenogenetic Stem Cells In addition ISCO will present two posters detailing progress in our pre-clinical metabolic liver disease program and recent achievements with our "safe" iPS cells, induced pluripotent stem cells that do not rely on viral vectors for the genetic reprogramming. The posters will be presented on Thursday, May 16, 2013 between 4:00 pm and 6:00 pm in Exhibit Hall C/D. About International Stem Cell … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting

Scientists Decode "Molecular Chatter" That Makes Cancer Cells Spread

Posted: Published on May 2nd, 2013

Featured Article Academic Journal Main Category: Cancer / Oncology Also Included In: Stem Cell Research;Biology / Biochemistry Article Date: 02 May 2013 - 0:00 PDT Current ratings for: Scientists Decode "Molecular Chatter" That Makes Cancer Cells Spread 4.5 (2 votes) 4 (2 votes) Principal investigator Russell Taichman, a professor at the University of Michigan (U-M) School of Dentistry in Ann Arbor, and colleagues, write about their discovery in the 30 April online issue of Nature Communications. It is becoming increasingly clear that cancer cells are wily, well-travelled adversaries that are capable of side-stepping the treatments we throw at them to try and stop them spreading. For instance, a recent study that produced a catalogue of the physical properties of cancer cells, found they are nimbler and more aggressive than healthy cells because they are better able to pass through small spaces, and they exert a greater force on their environment. Now Taichman and colleagues have discovered a set of molecular signals that causes them to go into overdrive and spread. For some time, scientists have known that tumors summon the body's healing cells, and this is a major reason cancer is difficult to treat. Think of a cancerous tumor as … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Scientists Decode "Molecular Chatter" That Makes Cancer Cells Spread

Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013

Posted: Published on May 2nd, 2013

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host a webinar on drisapersen with GlaxoSmithKline (GSK) on May 6, 2013 at 12 p.m. EDT for Duchenne parents and advocates. The purpose of the webinar is to update the Duchenne community about Phase II clinical trial results for GSKs drisapersen drug for the treatment of Duchenne muscular dystrophy, a progressive muscle wasting disease that impacts 1 in 3,500 boys. GSK investigator John Kraus will present and answer submitted questions. CureDuchenne is hosting the webinar in collaboration with Parent Project Muscular Dystrophy and the Muscular Dystrophy Association to enable the Duchenne community and GSK to come together to further understand the drisapersen update for potential Duchenne treatments. Boys with Duchenne are usually diagnosed before the age of 5, in a wheelchair by age 12 and most dont survive their mid-20s. There is currently no cure for Duchenne. To register for the Drisapersen Update webinar with the GSK on May 6 click here. Follow us on Facebook, Twitter and YouTube. About CureDuchenne CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013

Epilepsy patients find device can predict seizures

Posted: Published on May 2nd, 2013

In a world first, Australian doctors have found a way to predict the onset of seizures in people with epilepsy that does not respond to drug treatments. The finding, hailed by experts as a "major milestone", has the potential to dramatically improve the independence and treatment of millions of people living with the condition globally. Melbourne researchers reported in the Lancet Neurology medical journal on Thursday that a small device can be implanted in the brain to monitor electrical activity which can change before seizures occur. The technology, developed by US company NeuroVista, involves electrodes being surgically placed between the brain surface and the skull. The electrodes feed data to a device implanted under the skin of the user's chest which then transmits the information to a wireless hand-held device that calculates the probability of a seizure. Advertisement Lead author of the report and a neurologist from the University of Melbourne, Professor Mark Cook, said the hand-held device which can be carried in a handbag or pocket has three coloured lights to warn patients of a low, moderate or high risk of an impending seizure. It also beeps and vibrates to alert people to the results. He said the device, … Continue reading →

Comments Off on Epilepsy patients find device can predict seizures

Page 5,366«..1020..5,3655,3665,3675,368..5,3805,390..»